Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in